Castelli, Francesco

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science

interferon and immune responsesSARS-CoV-2 and COVID-19 Research

Cited by 2,662

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science

interferon and immune responsesSARS-CoV-2 and COVID-19 Research

Cited by 2,229

Factors Associated With Surgical Mortality and Complications Among Patients With and Without Coronavirus Disease 2019 (COVID-19) in Italy

Doglietto, F., Vezzoli, M., Gheza, F., Lussardi, G. L., Domenicucci, M., Vecchiarelli, L., Zanin, L., Saraceno, G., Signorini, L., Panciani, P. P., et al. (2020) · JAMA Surgery

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 356

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial

Ogbuagu, O., Molina, J.-M., Chetchotisakd, P., Ramgopal, M. N., Sanchez, W., Brunetta, J., Castelli, F., Crofoot, G. E., Hung, C.-C., Ronot-Bregigeon, S., et al. (2025) · Clinical Infectious Diseases

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 44

The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience

Pezzaioli, L. C., Quiros-Roldan, E., Paghera, S., Porcelli, T., Maffezzoni, F., Delbarba, A., Degli Antoni, M., Cappelli, C., Castelli, F., & Ferlin, A. (2021) · Infection

Hormonal and reproductive studiesHIV-related health complications and treatments

Cited by 27

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 6